alexa Melatonin and Multiple Sclerosis: An Outline on Current Evidences | Open Access Journals
ISSN: 2155-9562
Journal of Neurology & Neurophysiology
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Melatonin and Multiple Sclerosis: An Outline on Current Evidences

Seyed-Hossein Abtahi1,3, Zahra Nasr1,3, Niloofaralsadat Nourian4, Seyed-Mojtaba Abtahi6, Fatemeh Abrishamchi5, Masoud Etemadifar1 and Mahboobeh Fereidan-Esfahani1,2*

1 Isfahan Research Committee of Multiple Sclerosis (IRCOMS), Isfahan University of Medical Sciences, Isfahan, Iran

2 Persia Research Center, Sady hospital, Isfahan, Iran

3 Medical Students’ Research Center, Isfahan University of Medical Sciences, Isfahan, Iran

4 Medical School, Islamic Azad University, Najafabad Branch, Najafabad, Iran

5 Department of Neurology, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran

6 Department of Otolaryngology/Head and Neck Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Corresponding Author:
Mahboobeh Fereidan-Esfahani
Isfahan MS Society No.2, Behesht Building
Bozorgmehr Ave., Isfahan, Iran
Tel: +989380283952

Received date: December 13, 2013; Accepted date: January 30, 2014; Published date: February 15, 2014

Citation: Abtahi SH, Nasr Z, Nourian N, Abtahi SM, Abrishamchi F, et al. (2014) Melatonin and Multiple Sclerosis: An Outline on Current Evidences. J Neurol Neurophysiol S12:008. doi:10.4172/2155-9562.S12-008

Copyright: © 2014 Abtahi SH, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Neurology & Neurophysiology


To date, in the literature, there have been a number of studies regarding the effects of Melatonin on MS course
and pathogenesis; herein, we wish to bring a concise outline on such evidences to the readership.


Melatonin; Multiple sclerosis; Sleep; Vitamin D


Multiple sclerosis (MS) is a complex demyelinating disorder resulting from multiplicity genetic and environmental risk factors. The substantial rise in MS prevalence and changing in the epidemiological pattern of MS have been shown in several population-based studies [1].

To date, in the literature, there have been a number of studies regarding the effects of Melatonin on MS course and pathogenesis; herein, we wish to bring a concise outline on such evidences to the readership.

Melatonin is mainly produced by pineal gland in dark phase and metabolized to principal metabolite 6-hydroxy-melatonin in the liver. Although, melatonin secretion has a constant rhythmic amplitude in each individual, significant differences has been shown among the general population [2].

Varied factors such as, high oxygen utilization; high c1oncentration of polyunsaturated fatty acids; low concentrations of cytosolic antioxidants; and, existence of transition metals such as iron involved in the generation of hydroxyl radicals make the brain susceptible to radical damage [3]. On one hand, some theories for the role of oxidative stress, autoimmunity and inflammatory process have been proposed in the pathogenesis of MS lesions. On the other hand, the anti-inflammatory, immunomodulatory and antioxidative effects of melatonin have been previously well established [4]; theoretically, these protective effects could play an important role in MS pathogenesis, course and complications such as fatigue [5].

Some previous studies showed that the level of melatonin or its metabolites decreases in MS patients compared with normal controls and inversely might be correlated with MS disease activity [6,7]. Such findings could have been explained by the anti-inflammatory property of melatonin.

Complications such as sleep restriction and depression are common in MS. Melatonin secretion is directly affected by environmental stimuli such as light and in turn, regulates the sleep circle in humans. A recent study showed significant decrease in melatonin levels among patients with sleep restriction [6]. Relatively, increased risk of MS has also been shown in young patients with shift work [8]. Moreover, one of the routine treatments of MS patients i.e. Interferon-beta may result in increased level of serum melatonin, though, this medication was not shown to improve the sleep efficacy. Such results might have been due to other factors along with melatonin which could play a role in sleep disturbances; e.g. urinary complications; spasticity and muscle cramps; fatigue; depression; disease activity; and, location of CNS lesions.

In some reports, depression -- another common complication of MS -- has been associated with low nighttime level of serum melatonin [9]; a finding which can be speculatively explained by melatonin dysregulation in MS. However, some other studies [10,11] do not support such a linkage; this could be due to other confounding factors e.g. antidepressant agents, beta blockers or hormonal drugs, as well as age, light exposure and season.

Impressive geographical gradient with significantly higher incidence of MS in increasing latitude led scientists to evaluate the role of vitamin D in MS patients and also its relation with melatonin secretion [12,13]. Recently, Golan et al. [14] found that melatonin level is inversely related to 25-OH-D level. They adhered to the notion that “25-OH-D can bring a ‘message of light’ to the pineal gland and consequently decrease melatonin synthesis”. Such possible interconnectivities between vitamin D and melatonin are an engaging issue to be opened up in future works. Further clinical and experimental studies should consider the concurrent role of melatonin and vitamin D on MS-related symptoms and disease course.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11567
  • [From(publication date):
    specialissue-2014 - Aug 24, 2017]
  • Breakdown by view type
  • HTML page views : 7820
  • PDF downloads :3747

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

1-702-714-7001Extn: 9037

Business & Management Journals


1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

1-702-714-7001 Extn: 9042

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version